Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States

Table 2 Baseline demographic and clinical characteristics¹ of eligible patients with GEC by index treatment regimen (mean ± SD) n (%)

	5-FU (n = 257)	CAP (n = 105)	5-FU combination (n = 344)	CAP combination (n = 76)	Any 5-FU (n = 540)	Any CAP (n = 166)	Total (n = 1013)1
Demographics2
Female	180 (70.0)	77 (73.3)	264 (76.7)	61 (80.3)	395 (73.2)	127 (76.5)	746 (73.6)
Mean age (yr)	63.2 (12.1)	63.6 (12.4)	60.3 (11.6)	60.4 (12.0)	61.7 (11.9)	63.0 (12.3)	62.6 (11.8)
Covered by Medicare	127 (49.4)	50 (47.6)	126 (36.6)	30 (39.5)	231 (42.8)	78 (47.0)	465 (45.9)
Residing in urban area	202 (78.6)	83 (79.1)	259 (75.3)	64 (84.2)	416 (77.0)	136 (81.9)	784 (77.4)
Clinical characteristics3
CCI	5.5 (3.2)	5.9 (3.0)	4.9 (3.0)	5.1 (3.1)	5.1 (3.1)	5.5 (3.0)	5.2 (3.1)
CDS	4.2 (3.5)	4.5 (3.7)	4.6 (3.4)	4.3 (3.5)	4.4 (3.4)	4.6 (3.6)	4.6 (3.5)
Metastatic disease4	161 (62.7)	55 (52.4)	248 (72.1)	47 (61.8)	364 (67.4)	97 (58.4)	675 (66.6)
Previous treatment
Surgery	125 (48.6)	27 (25.7)	46 (13.4)	11 (14.5)	154 (28.5)	34 (20.5)	239 (23.6)
Radiotherapy	115 (44.8)	25 (23.8)	162 (47.1)	15 (19.7)	252 (46.7)	40 (24.1)	410 (40.5)
Baseline expenditure ($)5	5479 (4730)	4965 (6277)	4598 (5019)	4178 (4005)	5014 (5061)	4607 (5573)	4763 (5193)

Marketscan Commercial and Medicare Databases: 2000-2005. CAP: Capecitabine.

¹One patient may receive multiple regimens; therefore, the sum of patients in each episode will exceed the total number of study-eligible patients;

²Demographics measured on the date the first study-eligible chemotherapy was administered;

³Clinical characteristics measured in the 6 mo before the first study-eligible chemotherapy, unless otherwise specified;

⁴Measured using all available data prior to episode onset;

⁵Mean per month over 6 mo pre-index.